In the wake of the new patent reform law, discovery will be a significant addition to administrative proceedings that review the validity of issued patents. A medical device company’s lawsuit against the patent office foreshadows likely fights about the scope of discovery in these proceedings, which are expected to spike under the new law.
Cordis Corp., a Johnson & Johnson subsidiary, sued the U.S. Patent and Trademark Office and its director, David Kappos, on Jan. 26 in the Eastern District of Virginia. At issue was the PTO’s refusal to let Cordis subpoena companies challenging its patents in an inter partes re-examination. The PTO has stated its policy is not to allow discovery in these review proceedings.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
